Novavax said on Wednesday U.S. regulators asked the company to produce more data on its COVID-19 vaccine if it gets full approval, sending the drugmaker's shares soaring and easing concerns around the ...

B. Riley analyst Mayank Mamtani lowered the firm’s price target on Agenus (AGEN) to $8 from $11 and keeps a Buy rating on the shares. The firm ...